AstraZeneca’s Forxiga receives positive advice from Scottish Medicines Consortium
AstraZeneca announced that the Scottish Medicines Consortium (SMC) has issued positive advice for use of its Forxiga, a selective and reversible inhibitor of sodium-glucose co-transporter-2, as part of a triple therapy regimen for type 2 diabetes.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Pharmaceuticals